ABT 3Q24 Results by Business Segment [pre] %Corp YoY Growth Segment Sales (const currency) Medical devices* 45% +13% Diagnostics 23% +1%† Nutrition 19% +8% Pharmaceuticals‡ 13% +7%[/pre]60% of overall corporate sales were ex-US. *Includes diabetes care. ‡Branded generics and biosimilars in emerging markets. †Excluding COVID diagnostics, 3Q24 diagnostics sales were +3% YoY in constant currency. (COVID-diagnostics sales were $265M in 3Q24 vs $305M in 3Q23.)